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Background: Lung deposition of inhaled steroids, likely to be of benefit in the anti-inflamma-
tory treatment of asthma in young children, is low. This is explained by age specific anatomical
and physiological characteristics as well as poor cooperation with aerosol therapy. However,
total lung deposition and the ratio of lung deposition to oropharyngeal deposition are key
determinants of clinical efficacy and of systemic side effects of aerosolized drugs.
Objectives: The aim of this study was to determine lung deposition and ratio of lung deposition
to oropharyngeal deposition using a modified vibrating membrane nebuliser to deliver budeso-
nide with a small particle size, taking into account the needs of young children.
Patients and methods: Ten asthmatic children (5 males), mean age 20.3 months (range 6e41
months) inhaled radiolabelled budesonide (MMD 2.6 mm) through a modified vibrating
membrane nebuliser (modified PARI e-Flow). Lung deposition expressed as a percentage ofdiproprionate; CFC, chlorofluorocarbon; DTPA, diethylenetriamine penta-acetic acid; HFA, hydro-
MMAD, mass median aerodynamic diameter; P:C ratio, peripheral to central ratio; SD, standard
t of Paediatrics, University Children’s Hospital, 3010 Bern, Switzerland. Tel.: þ41 31 632 21 11;
sel.ch (K.G. Schueepp).
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Aerosol delivery of nebulised budesonide 1739the emitted dose was measured using scintigraphy and the ratio of lung deposition to oropha-
ryngeal deposition was calculated.
Results: Mean lung deposition (SD) expressed as percentage of emitted dose and mean lung to
oropharyngeal deposition ratio (SD) in quietly breathing children (nZ 5) and in children crying
during inhalation were 48.6% (10.5) versus 20.0% (10.9), and 1.0 (0.3) versus 0.3 (0.2), respec-
tively.
Conclusions: We have shown that by using an improved age-adjusted complementary combina-
tion of delivery device and drug formulation to deliver small particles, lung deposition and
ratio of lung deposition to oropharyngeal deposition in young asthmatic children is highly
improved. But the main factor limiting aerosol delivery in this age group remains cooperation.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Inhaled steroids play a leading role in anti-inflammatory
treatment of asthma.1,2 It is generally believed that the
inhaled route allows efficient delivery of drugs to the target
sites within the airways.3 However, lung deposition results
in young children inhaling from a conventional nebuliser are
low and have been shown to be between 0.1% and 8%.4 High
oropharyngeal deposition of nebulised steroids in young
children carries the risk of local adverse effects.5 Systemic
side effects rising from chronic drug therapy are for addi-
tional concern.2,6 Therefore, improved delivery of drugs to
the airways of young children as well as an improved ratio
of lung deposition to oropharyngeal deposition is likely to
be of clinical benefit. Despite that as already shown
decades ago7,8 particles size is a major factor influencing
aerosol delivery, it is not taken into account into devel-
oping age specific delivery devices for children. We have
shown by a recent in vitro study that particle size is a major
factor determining lung deposition of an aerosolized drug in
young children.9 Children do often not cooperate while
inhalation leading to increased drug deposition in the upper
airways arising from increased impaction while crying.10 In
addition lung deposition is higher when inhaled steroids are
delivered with a particle size of a Mass median aerodynamic
diameter (MMAD) of 2.5 mm compared to 4.5 mm in three
year-old asthmatic children.3 Options for an efficient
aerosol therapy in early life are limited as most nebulisers
are developed for adults and only little devices delivering
efficiently small sized particles are available. A small
particle size to reach the lungs of young children and
a short inhalation procedure due to reduced cooperation in
this age group is crucial. Recently developed nebulisers
such as the PARI e-flow are aimed to generate a high
delivered dose and a small particle size. The aerosol
generation principle of this new nebulisers is based on
a membrane perforated with small holes and a piezo-
electric element exciting the membrane to vibrate thus
droplets ejects through the holes and creating a thin
aerosol.11 Compared to former nebulisers the PARI e-Flow
is an efficient, convenient device. It produces an aerosol
with a small particle size, an exchangeable membrane
allows additionally to vary the particle size. The aim of the
present study was to assess lung deposition of small-
particle sized nebulised budesonide in young asthmatic
children using a modified PARI e-Flow and to address the
influence of cooperation upon lung deposition.Methods
Study subjects
Asthmatic children were recruited, each had asthma at
a stable stage judged as: no hospital visits within the
previous two weeks, no respiratory infection, no antibi-
otics, no oral corticosteroids, no increase in inhaled
steroids or bronchodilators. None of the children had
previously participated in a research project involving
radiation. The parents were given information concerning
possible risks using radiolabelled drug. The total radiation
dose received was explained to be equal to what is normally
received from natural sources over a 3e5 week period or
from two return plane trips from Perth to Sydney.
Drug solution and delivery device
Drug solution consisted of Budesol (Budesonide 200 mg/ml,
PARI GmbH Starnberg, Germany, commercially non avail-
able, physico-chemical characteristics; viscosity 1.07G
0.02 mPa/s, surface tension 38.82G 0.43 mN/m, 4.25 pH,
Osmolality 0.282G 0.001 osmol/kg). This solution favours
a high drug deposition and decreased inhalation times due to
its high drug concentration, however unfavourable aspects
being the relatively high viscosity and stickiness to the wall
of the nebuliser chamber. Budesol was nebulised by
a modified perforated vibrating membrane nebuliser
(e-Flow Baby, PARI GmbH Starnberg, Germany). The
e-Flow Baby functional prototype is a modified version of
the PARI e-Flow nebuliser.11 The following modifications
have been made: Mouthpiece and expiratory valve were
removed, the mixing chamber was shortened and dead
space reduced from 75 ml to 25 ml. Mean (SD) total output
rate (TOR) was 0.16 g/min (0.05 g/min), median mass
diameter was 2.6 mm, head efficiency, defined as head
output rate to electrical power, was 1.9 g/J.
Radiolabelling of budesonide
Budesol was labelled as follows: Based on a given fill
volume 0.2 mL of 99mTechnetium bound to diethylenetri-
amine penta-acetic acid (DTPA, Radpharm Scientific,
Australia) was mixed with 0.8 mL of budesonide solution
and vigorously shaken on a mechanical mixer (Multimix,
Ratek Instruments, Australia) for 15 min.
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measuring particle size distribution of labelled and unla-
belled nebulised budesonide solution compared to distri-
bution of radioactivity using an Andersen Impactor
(Thermo-Andersen, Smyrna, GA, USA) driven at a contin-
uous flow of 28.3 L/min. Mean room temperature was
22.7 C (range 20.1e25.1) and mean humidity was 50.7%
(range 40.0e63.0%)
Nebuliser, stages, jet and throat were subsequently
washed with 10 ml of Methanol. The absolute filter (Glas-
microfibre filters, 934-AH, Whatman, USA) was washed with
30 ml of Methanol. The absorbance of budesonide (wave-
length 243 nm)12 in each wash was assessed with a spec-
trophotometer (Shimaddzu Scientific UV-1601, Japan). The
concentration of budesonide was calculated using the
absorbance of a solution of a known concentration of
budesonide. The standard curve for budesonide was linear
(r2Z 1) for concentrations between 0 and 30 mg/l.12,13
Distribution of radioactivity of each labelled wash was
measured using an ionization chamber (Atomlab 200 dose
calibrator; Gammasonics, Sydney, NSW, Australia). The
particle size distribution of labelled budesonide (runsZ 17)
was then compared to the particle size distribution of
unlabelled budesonide (runsZ 23). This was done to
confirm that 99mTechnetium bound to DTPA was a suitable
marker of budesonide. On each study day particle size
distribution of radiolabelled budesonide was tested.
Inhalation procedure
All children inhaled two puffs of Ventolin (Salbutamol
100 mg/actuation, Glaxo SmithKline, Australia) through
a holding chamber (Babyhaler, Glaxo SmithKline,
Australia) prior to nebulisation. The fill in volume given to
each patient was adjusted on each study day so that
patients would not receive a dose exceeding 2 mega-
becquerels (MBq) in total dose. Nebulised drug was
administered using a tightly sitting face mask (Sure Seal,
1273 pediatric, Hudson RCI, Durham, USA), a round shaped
face mask with an inflatable rim. Nebulisation procedure
was accomplished by the parents, no prior instruction was
given to reproduce conditions as at home. A tight face mask
seal was visually controlled by the authors and if any leak,
i.g. visibly escaping aerosol, was detected, parents were
advised for correction. Toddlers were held upright, older
children sat on their parents lap. Children were distracted
by television. If children started to cry one single inter-
ruption was given, if after the interruption children started
to cry again procedure was continued without further break
and children declared as non-cooperative.
Assessment of in vivo distribution of radioactivity
Assessment of the distribution of radioactivity depositing in
the patients was done as previously described by Roller
et al.13 A flood source containing 37 MBq of radioactivity
was used for attenuation of activity due to absorption by
body tissues. Attenuation factors were determined for
every patient. After inhalation procedures an anterior and
posterior image of the chest and abdomen as well as
a lateral image from the upper airways was obtained usinga gamma camera (GCA 7200DI, Toshiba Australia; Perth,
WA, Australia). Collection time was 2 min for each image.
Areas of interests were defined for each of the images and
separate count rates were determined for the right and the
left lung (i.e. lung deposition), mouth, throat, esophagus
and stomach (i.e. oropharyngeal deposition). Each count
rate was corrected for background counts and attenuation
and the geometric means of corresponding anterior and
posterior count rates were calculated. The peripheral to
central deposition (P:C ratio) was quantified using the
method described by O’Doherty et al.14 The emitted dose
as the amount of drug leaving the inhalation device and
consequently inhaled by the patient was hence calculated
as follows; emitted doseZ nominal dose e (device and
face mask). The dose deposited in the lungs was then
expressed as percentage of the emitted dose thus results
are not compromised by different amounts of drug left
within the nebuliser due to different inhalation times
resulting from variant cooperation. Exhaled aerosol and
facial deposition were not assessed separately. After
picture collection patients were urged to rinse their mouth
with water.
Statistical analysis
Comparative statistics included two-sided t-tests and a p-
value 0.05 was considered as significant. Statistics were
performed with Systat, version 10, Systat Inc., Chicago IL,
USA. Descriptive statistics are given as mean (standard
deviation, SD) unless otherwise indicated as variables were
normally distributed.
Ethics
The study was approved by the institutional ethics
committee (Princess Margaret Hospital for Children, Perth,
WA, Australia). Informed consent was obtained from the
parents.
Results
Fig. 1 shows the in vitro particle size distribution from the
commercial unlabelled budesonide solution, the labelled
budesonide solution and distribution of the radioactivity.
The drug particle size distribution from unlabelled and
labelled budesonide, compared with the distribution of the
radioactivity, assessed with an Anderson impactor showed
a good correspondence. The fine particle fraction
(<4.7 mm) as a percentage of the total amount in the
impactor was 82%, 76% and 84% for the unlabelled drug,
labelled drug and radiolabel respectively. The extra fine
particle fraction (<3.3 mm) as a percentage of the total
amount in the impactor was 79%, 74% and 82% for the
unlabelled budesonide, labelled budesonide and radiolabel
respectively.
Demographic data of the ten enrolled subjects (5
males), mean age 20.3 months (range 6e41 months) and
corresponding lung deposition, lung to oropharyngeal
deposition ratio expressed as a percentage of the emitted
dose as well as peripheral to central ratio are shown in
Table 1. Mean age of the non-cooperative group was 14.4
Figure 1 The in vitro particle size distribution from the
commercial unlabelled budesonide solution, the labelled
budesonide solution and distribution of radioactivity using an
Andersen impactor. Data are presented as mean and SD.
Aerosol delivery of nebulised budesonide 1741months (4.7) and 26.2 months (14.1) of the cooperative
children.
The mean fill in volume given to each patient (0.7 ml,
range 0.5e0.8 mL) was adjusted on each study day so that
patients would not receive a dose exceeding 2 mega-
becquerels (MBq) in total dose. Prior to the study the effect
of different fill in volumes on nebuliser performance was
tested and no effect was observed.
Mean nebulisation time was 4 min 46 s (Range 2 min 10 s
to 8 min 36 s). This wide range is mostly due to different
cooperation both from parents and as well from children
thus administration could not always be carried out until
the end, i.g. nebulisation untill dryness. If the fluid was
nebulised untill dryness, approximately 5% of the nominal
dose was left at the bottom of the fluid feed according to
prior assessments of the manufacturer.Table 1 Characteristics of subjects (nZ 10) together with coop
emitted dose, lung to oropharyngeal deposition ratio and periphe
Gender Age
(months)
Height
(cm)
Weight
(kg)
Crying Total lung
deposition
(percentage of
the emitted dose)
F 6 70 8.7 No 30.6
F 8 64 8 Yes 14.6
F 12 52 9.6 Yes 8.0
M 14 77 8.5 Yes 16.5
M 19 84.5 11.5 Yes 36.6
M 19 84 14.5 Yes 24.0
F 21 89 16.4 No 52.9
F 25 85 12.3 No 56.4
M 38 107 19.6 No 54.7
M 41 99 17.7 No 48.2Overall mean lung deposition (SD) was 34.3% (18.2%).
Mean lung deposition (SD) was much higher in quietly
inhaling children (nZ 5, 48.6% (10.5%)) than in children
crying during inhalation (nZ 5, 20.0% (10.9%)), pZ 0.003;
two-sided t-test. Overall mean lung deposition to oropha-
ryngeal deposition ratio (SD) was 0.6 (0.5). Mean lung
deposition to oropharyngeal deposition ratio is much higher
in cooperative children than in non-cooperative children
(1.00 (0.34) versus 0.27 (0.19), pZ 0.005; two-sided t-
test). Overall mean peripheral to central ratio (SD) was 2.28
(0.77).
Figs. 2 and 3 show the deposition picture of a non-
cooperative child (Fig. 2, age 12 months, lung deposition
8.0%) and a cooperative child (Fig. 3, age 25 months, lung
deposition 56.4%).
Discussion
In our study, we have shown that lung deposition of inhaled
budesonide in infants and preschool children with asthma
can be higher when a combination of delivery device and
drug formulation suitable for this age group is used
compared to our former study.3 However, despite technical
aspects being an important issue for efficient aerosol
delivery to the lungs of young children, the main factor
determining lung deposition remains cooperation.
Based on our findings that lung deposition in quietly
inhaling breathing children between 21 and 41 months is
relatively consistent with values between 48% and 56%, we
conclude that 2.6 mm is a suited particle size to obtain high
and constant drug delivery to the lungs of toddlers. As lung
deposition in a quietly breathing infant is 30%, particle size
for high and constant drug delivery in infants is likely to be
even smaller. Our finding of an improved particle size of
2.6 mm leading to high and constant lung deposition in
toddlers is in accordance to our recent in vitro finding9 as
well as to the in vitro findings of Janssens et al. using
a pressurised metered-dose inhaler (pMDI).15 Lung deposi-
tion in our present study is much higher compared to
deposition studies using larger particles. Lung deposition
using a pMDI without priming was shown to be only 1.97%.16eration, total lung deposition expressed as percentage of the
ral to central ratio (P:C ratio).
Total oropharyngeal
deposition
(percentage of
the emitted dose)
Lung:Oropharyngeal
deposition ratio
Mean peripheral:
central ratio
69.4 0.4 1.3
85.4 0.2 3.3
92.0 0.1 2.1
83.5 0.2 1.2
63.4 0.6 1.7
76.0 0.3 2.7
47.1 1.1 2.5
43.6 1.3 1.7
45.3 1.2 3.1
51.8 0.9 3.0
Figure 2 Deposition picture of a non-cooperative child (age
12 months, lung deposition 8.0%). Figure 3 Deposition picture of a cooperative child (age 25
months, lung deposition 56.4%).
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4.2 mm was 1.5%.17 Results of different deposition studies
are difficult to compare as lung dose is calculated and
expressed with differing methods. However, the huge
differences seen between our study and previous work
cannot be explained only by methodological differences. In
addition, we have shown that cooperation has a strong
effect upon efficient lung deposition of nebulised budeso-
nide. This is in accordance to a study of Amirav et al.18
showing that with increasing stress of the child during
aerosol administration, deposition in the upper airways and
in the gastrointestinal tract is markedly increased. In our
study, cooperative children were older compared to the
non-cooperative children, 26.2 months and 14.4 months
respectively. This finding might reflect the clinical situation
with younger children generally being less cooperative
during aerosol administrations. However, we have shown
that with an improved combination of device and drug
formulation a high lung deposition of 30% can even be
achieved in the youngest age group. This stresses the need
to find means to improve cooperation with aerosol therapy
in young children.
Mask and facial deposition were not assessed separately
in our study but has been addressed in other studies.
Aerosol delivery to young children has been shown to be
dependent both on facemask design and on face to face-
mask seal. It has been shown that drug delivery can be
improved using a round facemask with a flexible rim similar
to the one used in our study.19 In addition, it has beenshown in several studies that a good seal of face mask to
face is crucial for efficient aerosol delivery.20e23 No
difference upon cooperation was found between different
masks, thus it is likely that facemask design has no influ-
ence on cooperation. It is more likely that young children
simply do no like to have any face mask pressed on their
face. In the study of Sangwan et al.24 all investigated face
masks leaked aerosol with significant facial and eye depo-
sition. Their data suggest that the safest combination is
a device with a small MMAD (below 3.3 mm) and a T-mask
fitting. However visualising the deposition pictures (Figs. 2
and 3), facial deposition is likely to be a small portion of the
overall gastrointestinal deposition and to be in a similar
range compared to previously reported data (between 3.6
and 8.4%).19
Lung deposition of modern inhaled steroids does not only
determine clinical efficacy but also potential side effects
due to systemic absorption in the lungs.25 It has been shown
when using a hydrofluoroalkane (HFA) formulation with
a smaller particle size that the systemic bioavailability due
to a higher intrapulmonary deposition was much higher
compared to a chlorofluorocarbon (CFC) formulation with
a bigger particle size.26 Szefler et al.27 showed that asthma
control can be well maintained in children when switching
from CFC beclomethasone dipropionate (BDP) to an HFA-
BDP at half the daily dose reflecting a higher lung dose. But
one has to be aware that most aerosols are presumably on
the upper flat part of the dose response curve and
Aerosol delivery of nebulised budesonide 1743therefore a reduction of the dose is likely to be still
effective in many aerosols. Another study showed that
extra fine HFA-BDP provided long-term maintenance of
asthma control at half the dose compared to CFC-BDP, but
no differences regarding to growth or other systemic
effects.28 Hence when treating with corticosteroids moni-
toring of potential side effects is necessary.
The e-Flow Baby is a recently developed modified
version of the PARI e-Flow nebuliser11 thus only little
comparable data is published to date. Technicalities and
physico-chemical characteristics of a drug solution influ-
ence aerosol production. While mostly particle size
decreased compared to other conventional nebulisers such
as the PARI LC STAR shown for Sultanol (albuterol),
Ventolin (albuterol), Pulmicort suspension (Budsonide),
and PARI budesonide suspension,29 particle size increased
when Atrovent (ipatropium bromide) was nebulised by the
e-Flow.30 This additionally stresses that the combination
of a drug solution and delivery device is crucial and might
differ for each combination. The short inhalation time of
the e-Flow has been shown to be preferable to other
nebulisers and to improve adherence to aerosol admins-
tration, especially in chronically ill patients with the need
of a daily based inhalation therapy.31,32
Lung deposition results in young children inhaling from
a conventional nebuliser emitting larger aerosol particles
are low and have been shown to be between 0.1% and
8.0%.3 From these results it could be expected that neb-
ulised steroid therapy at recommended doses in this age
group is inefficacious. However, there are a series of
studies showing efficacy and safety of median daily doses of
0.5e1.0 mg of nebulised budesonide in 6 months to 9 years
old asthmatic children.33e37 These studies have included
a wide age range of children and have not looked at the
efficiency in young children (infants and preschool children)
separately and may therefore not be valid for this specific
age group. There is only one study looking at the safety of
0.5 mg and 1.0 mg of larger particle sized nebulised bude-
sonide in infants.38 Whereas the authors have shown these
doses to be safe, they could not find a significant difference
in symptom free days and the global assessment of patient
health. This finding is likely explained by the fact that the
dose reaching the airways in these infants has been too low
to actually reach clinical efficacy and to cause systemic
adverse effects due to intrapulmonary absorption. Another
explanation that clinical studies in infants and young
children with obstructive airway disease are difficult to
interpret as obstructive airway disease in this age group
consists of a heterogenous group of diseases. It could be
argued that clinical efficacy of large particle sized
nebulised inhaled steroids could be achieved by simply
increasing the nebulised dose. This hypothesis is supported
by the finding that while in certain clinical situations,
where steroids are thought to be an effective treatment,
studies using dose recommendations based on national and
international guidelines using currently available delivery
systems have failed to show a clinical effect, while other
studies using much higher doses than recommended have
been able to find a clinical benefit.39e42 However, simply
increasing the administered dose leads to increased
oropharyngeal deposition with the potential of local side
effects as well as increased costs.4Radiolabelled studies have recently given rise to criti-
cism.43 Deposition studies using radioactivity are carried
out to obtain information that could not be obtained in
other ways such as deposition pattern within the airways.
Despite the increasing number or deposition studies there
remains an unease regarding radioactivity. There is no
standard concerning radioactivity leading to different
approaches making it difficult to compare the results from
different studies. Likewise, there is no threshold dose
concerning clinical effects of radioactivity. The doses used
to date are considered to be at extremely low risk,
particularly when using tracers with a short half time
residency and a rapid clearance from the lungs resulting in
an exposure equivalent to a few weeks background radi-
ation and much less than with a computer scan of the
chest performed. Being aware of this unease we exposed
the children to a minimal required dose. This study
displays the deposition pattern within the airways using
a smaller particles size and displays it additionally in
dependence of compliance, results that could not be
obtained with another study design. Moreover, this study
provides clinical important information showing for the
first time that a high lung deposition in very young children
can be achieved taking into account the special needs of
small children.
In summary, we have shown that by using an improved
complementary combination of delivery device and drug
formulation addressing the needs of young children, lung
deposition as well as the ratio of lung deposition to
oropharyngeal deposition of nebulised steroids can be
greatly improved in this age group. The amount of drug
reaching the lungs is an important parameter in the eval-
uation and characterisation of drug device combinations.
Results from radiolabelling studies are rare but important
for established and new drugs used for the treatment of
respiratory disease as the amount of drug reaching the
lungs and its distribution are of clinical importance. With
a high lung deposition and less upper airway deposition on
account of a smaller particle size, decreased local and
systemic side effects along with improved clinical effi-
ciency of inhalation therapy in children and in consequence
lower costs can be achieved. A short inhalation procedure
due from improved efficacy is crucial in this age group as
cooperation is limited. Moreover, improved aerosol delivery
to young children may not only improve the efficiency of
nebulised steroids, but may also offer new potentials to
improve therapeutic options for the treatment of other
respiratory diseases in early childhood using various drugs.
However, despite technical aspects being important, the
main factor determining lung deposition in young children
remains cooperation.
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